A humanized anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells, reducing antigen presentation, proinflammatory cytokines, and B-cell activity in the CNS.
Humanized anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity, thereby reducing antigen presentation, proinflammatory cytokine release, and B-cell activity in the CNS.
Anti-CD20 IgG1 binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC by immune effector cells, leading to lysis/depletion of CD20+ cells.
A chimeric anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells.
Chimeric anti-CD20 IgG1 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis, reducing B-cell antigen presentation and proinflammatory cytokine production.
Binds CD20 on B cells and induces killing via Fc-mediated ADCC, complement-dependent cytotoxicity (CDC), and CD20 crosslinking–induced apoptosis.
A fully human anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells.
Fully human anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).
Ofatumumab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated effector killing (ADCC/ADCP), leading to lysis and depletion of CD20+ cells.
Autologous anti-CD19 CAR T-cell therapy that targets CD19 and kills malignant B cells via T-cell cytotoxicity.
Autologous T cells engineered to express an anti‑CD19 chimeric antigen receptor bind CD19 on malignant B cells, triggering CAR signaling (CD3ζ with costimulation), T‑cell activation/expansion, cytokine release, and perforin/granzyme‑mediated cytotoxic killing of CD19‑positive cells.
Anti-CD19 CAR T cells bind CD19 and, upon CAR signaling, directly lyse CD19+ cells via perforin/granzyme and death-receptor pathways.
Anti-CD20 monoclonal antibody mediating ADCC, CDC, and apoptosis of B cells.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and kills them via Fc-mediated ADCC (NK/macrophages), complement-dependent cytotoxicity (CDC), and induction of apoptosis through CD20 signaling.